NCT07242638Phase 2Recruiting
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Use of Specific JAK Inhibition on Inflammatory Skin and Scalp Diseases in Down Syndrome R61AR084210
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Participants (registry)
- 56
- Start
- January 2026
- Primary completion
- March 2027 (planned)
- Study completion
- March 2028 (planned)
- Last registry update
- February 2026
- Countries
- United States
Conditions studied: Atopic Dermatitis, Alopecia Areata
Interventions: Abrocitinib
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.